New Drug To Curb Hepatitis C – Part 2 of 3
In the ADVANCE trial, 1088 patients with hepatitis C who had never been treated for the condition were randomly assigned to measure therapy for 48 weeks, or telaprevir combined with standard therapy for eight or for 12 weeks, followed by standard therapy alone for a total treatment time of either 24 or 48 weeks. The researchers found that 79 percent of those receiving Incivek for the longest aeon (24 weeks) had a “sustained response,” which basically means their hepatitis C was contained.
Among those receiving standard care, 44 percent had a steady response, the researchers noted. “We have entered a new era of therapy for hepatitis C, which enables us to cure many more patients than we could before,” said lead researcher Dr Ira M Jacobson, from Weill Cornell Medical College in New York City.
Incivek needs to be given along with pegylated-interferon and ribavirin. The researchers highbrow early on that Incivek alone reduces the direct of the virus, but later the virus can become resistant to the drug.
For the second study, called the REALIZE trial, 663 patients with hepatitis C who had failed standard therapy were divided into three groups. One faction received Incivek plus standard therapy, another group was started on pegylated-interferon and ribavirin and then had Incivek added. The third group received standard therapy alone.
Here, the researchers found up to an 88 percent ceaseless response in patients receiving Incivek, compared with a 24 percent sustained response in the standard treatment group. “These drugs represent a truthful milestone in the treatment of this disease,” said lead researcher Dr Stefan Zeuzem, a professor of medicine at JW Goethe University Hospital in Frankfurt, Germany. “There were very limited remedying options in the past, but now many patients have excellent chances to be cured, even if they already have advanced disease”.